Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

S. Korea Panel Recommends Restricting Painkillers To 15 And Older

This article was originally published in PharmAsia News

Executive Summary

South Korea's drug regulator is expected to accept a recommendation that certain painkillers be restricted to persons 15 years of age and older. Among the drugs on a list drafted by the Central Pharmaceutical Affairs Council were popular medicines such as Bayer Korea's Saridon-A and Samjin Pharm's Geworin because their active pharmaceutical ingredient is isopropylantipyrine. The council said in its recommendation to the South Korea FDA the drug can cause heart disorders and loss of consciousness and should not be available to people under the age of 15. (Click here for more

You may also be interested in...



Pipeline Watch: Vericiguat, Evinacumab Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

EMA Set To Discuss Safety Of Ranitidine

Following the announcement in the US that ranitidine drugs must be withdrawn from the market, the European Medicines Agency told the Pink Sheet it would decide on the fate of these medicines in the EU after wrapping up its own inquiry.

Alvogen Aims To Be First On EU Pazopanib

Alvogen believes it is the first company to file for a generic pazopanib rival to Novartis’ Votrient oncology brand in Europe.

UsernamePublicRestriction

Register

SC071271

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel